

Figure S1 Prediction of the role of *DNMT3A* in immunotherapy. (A) The heatmap exhibits a positive correlation between *DNMT3A* and immune checkpoint expression in various tumors. (B,C) Satellite images display the correlation between *DNMT3A* expression and TMB and MSI in different tumors. (D,E) The association between *DNMT3A* expression and patient survival in GSE91061 and VanAllen2015 cohort, as well as the response to immunotherapy. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. The full name of the TCGA abbreviations sees the website: <https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations>. TMB, tumor mutational burden; MSI, microsatellite instability; SD, stable disease; PD, progressive disease; CR, complete response; PR, partial response.




Figure S2 The GSEA of *DNMT3A*. The area of the circle represents the FDR value, and the red color shows high score. The full name of the TCGA abbreviations sees the website: <https://gdc.cancer.gov/resources-tcga-users/tcga-code-tables/tcga-study-abbreviations>. FDR, false discovery rate; NES, normalized enrichment score; GSEA, gene set enrichment analysis; TCGA, The Cancer Genome Atlas.